Matthew A. Cooper
Fondateur chez Inflazome Ltd.
Postes actifs de Matthew A. Cooper
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Directeur/Membre du Conseil | 01/01/2016 | - |
| Directeur Général | 01/01/2016 | - | |
| Fondateur | 01/01/2016 | - | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 20/07/2022 | - |
Historique de carrière de Matthew A. Cooper
Anciens postes connus de Matthew A. Cooper
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Akubio Ltd.
 Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Directeur Technique/Scientifique/R&D | 01/08/2001 | 31/05/2010 |
| Fondateur | 01/08/2001 | 31/05/2010 | |
| University of Cambridge | Corporate Officer/Principal | - | - |
Formation de Matthew A. Cooper
| University of Adelaide | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Australie | 2 |
| Irlande | 2 |
Opérationnelle
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Electronic Technology | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Akubio Ltd.
Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Electronic Technology |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
- Bourse
- Insiders
- Matthew A. Cooper
- Expérience
